Double-labeled probe for molecular imaging and use thereof
US-11020493-B2 · Jun 1, 2021 · US
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
US12054458B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12054458-B2 |
| Application number | US-202318186043-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 17, 2023 |
| Priority date | Sep 30, 2015 |
| Publication date | Aug 6, 2024 |
| Grant date | Aug 6, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of formula Number: 1 or a salt thereof 2. The compound or salt thereof according to claim 1 , wherein the compound or salt is lyophilized. 3. A composition comprising: (a) the compound and/or the salt thereof according to claim 1 ; and (b) optionally a pharmaceutically acceptable carrier. 4. The composition of claim 3 , wherein the composition further comprises an excipient. 5. The composition of claim 3 , wherein the composition is a buffered solution. 6. The composition of claim 3 , wherein the compound and/or a salt thereof, and optionally the pharmaceutical acceptable carrier, are lyophilized. 7. A compound of formula number: 1a or a salt thereof 8. The compound or salt thereof according to claim 7 , wherein the compound or salt is lyophilized. 9. A composition comprising: (c) the compound and/or the salt thereof according to claim 7 ; and (d) optionally a pharmaceutically acceptable carrier. 10. The composition of claim 9 , wherein the composition further comprises an excipient. 11. The composition of claim 9 , wherein the composition is a buffered solution. 12. The composition of claim 9 , wherein the compound and/or a salt thereof, and optionally the pharmaceutical acceptable carrier, are lyophilized.
Assignees
Inventors
Classifications
of the prostate · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
Antineoplastic agents · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Linear peptides containing at least one abnormal peptide link · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12054458B2 cover?
- The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
- Who is the assignee on this patent?
- Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls
- What technology area does this patent fall under?
- Primary CPC classification C07D213/61. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).